益佰制药股价小幅下跌 拟8000万元受让子公司股权

Group 1 - The stock price of Yibai Pharmaceutical is reported at 4.55 yuan, down 0.87% from the previous trading day, with an opening price of 4.66 yuan, a high of 4.75 yuan, and a low of 4.47 yuan, with a trading volume of 1,121,773 shares and a transaction amount of 518 million yuan [1] - Yibai Pharmaceutical's main business includes pharmaceutical manufacturing, medical services, and the health industry, with key products in the pharmaceutical sector covering chemical drugs, traditional Chinese medicine, and biological drugs, targeting treatment areas such as oncology, cardiovascular diseases, and gynecology [1] - The company announced plans to acquire 40.03% of the equity in its subsidiary Yibai Traditional Chinese Medicine Formula Granules Co., Ltd. for 80 million yuan, which will result in the company holding 100% of the subsidiary after the transaction [1] - In the first half of 2025, Yibai Pharmaceutical reported a revenue of 999.3 million yuan, a year-on-year decrease of 15.0%, and a net loss attributable to shareholders of 19.9 million yuan, which is an improvement compared to a loss of 106 million yuan in the same period last year [1]